Content area
Full Text
A 53-year-old woman developed hepatotoxicity following treatment with trastuzumab [dosage and route not stated].
The woman was diagnosed with Stage III B breast cancer following which, she underwent a neoadjuvant chemotherapy with doxorubicin, cyclophosphamide and docetaxel. Her neodjuvant chemotherapy was completed and adjuvant therapy with trastuzumab was started. After her 7th...